BRISTOL-MYRS SQUIB revenue breakdown overview

BRISTOL-MYRS SQUIB revenue for the last year amounted to 37.89 B CHF, the most of which — 37.89 B CHF — came from its highest performing source at the moment, Innovative Medicines, the year earlier bringing 42.68 B CHF. The greatest contribution to the revenue figure was made by United States — last year it brought BRISTOL-MYRS SQUIB 26.57 B CHF, and the year before that — 29.43 B CHF.